Overview of treatment approaches to osteoporosis

DOI Web Site Web Site Web Site 被引用文献1件
  • Bente L. Langdahl
    Endocrinology and Internal Medicine Aarhus University Hospital Aarhus Denmark

説明

<jats:sec><jats:label /><jats:p>Efficient therapies are available for the treatment of osteoporosis. Anti‐resorptive therapies, including bisphosphonates and denosumab, increase bone mineral density (BMD) and reduce the risk of fractures by 20–70%. Bone‐forming or dual‐action treatments stimulate bone formation and increase BMD more than the anti‐resorptive therapies. Two studies have demonstrated that these treatments are superior to anti‐resorptives in preventing fractures in patients with severe osteoporosis. Bone‐forming or dual‐action treatments should be followed by anti‐resorptive treatment to maintain the fracture risk reduction. The BMD gains seen with bone‐forming and dual‐action treatments are greater in treatment‐naïve patients compared to patients pretreated with anti‐resorptive treatments. However, the antifracture efficacy seems to be preserved. Treatment failure will often lead to switch of treatment from orally to parentally administrated anti‐resorptives treatment or from anti‐resorptive to bone‐forming or dual‐action treatment. Osteoporosis is a chronic condition and therefore needs a long‐term management plan with a personalized approach to treatment.</jats:p></jats:sec><jats:sec><jats:title>LINKED ARTICLES</jats:title><jats:p>This article is part of a themed issue on The molecular pharmacology of bone and cancer‐related bone diseases. To view the other articles in this section visit <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc">http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc</jats:ext-link></jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ